The News Review:

- Boston University Medical Center researcher honored
- Genstar Capital Completes $797 Million Acquisition of PRA Internationa…
- Thousands in research on compliance on drug
- Susan G. Komen for the Cure Announces Recipients of 2007 Komen…
- EMD Serono Announces Support of The Michael J. Fox Foundation for…

Boston University Medical Center researcher honored
eurekalert.org – Dec 13, 2007
Holick PhD MD was recently awarded the 2007 Eli Lilly Lecturer Award from the Canadian Society of Endocrinology and Metabolism (CSEM). Holick an internationally recognized expert in vitamin D and skin research received the award for decades of pioneering work that elucidated the important role vitamin D plays in a wide variety of chronic health conditions. Holick is a professor of medicine physiology and biophysics and director of the General Clinical Research Center at Boston University School of Medicine and Director of the Bone Healthcare Clinic at Boston Medical Center. The Eli Lilly Lecturer Award has been awarded to some of the most prominent endocrinologists in the world. CSEM represents over three hundred endocrinologists engaged in basic research or clinical practice in communities universities and industries across Canada. They also represent the interests of their members with respect to clinical practice academic training research funding and medical politics. After completing medical school at the University of Wisconsin in 1976 Holick joined the staff at the Massachusetts General Hospital where he did an internship in medicine while simultaneously initiating a basic and clinical research program on the photobiology of vitamin D.

Genstar Capital Completes $797 Million Acquisition of PRA Internationa…
Free with registration – PR Newswire – AccessMyLibrary.com – Dec 13, 2007
–>CPYRIGHT 2007 PR Newswire Association LLC SAN FRANCISC Dec. “ur new status as a private company will enable our entire work force to be even more focused on attaining our common goal to provide outstanding clinical research trials for our clients” said Terrance. CPYRIGHT 2007 PR Newswire Association LLC.

Thousands in research on compliance on drug
Joy nline – Dec 13, 2007
There have been some complaints about adverse drug reaction among some users of artesunate-amodiaquine and the study would help address some of these challenges. The study is a follow up to a project conducted in the area on compliance among the population in adhering to instructions on taking artesunate amodiaquine when administered to patients directly at the health facility level and when patients are asked to go home and administer the drugs themselves. Dr Kwaku Poku Asante a Clinical Research Fellow at the KHRC told Journalists from the African Media and Malaria Research Network on a visit to the centre that about 90 per cent of people who took part in the earlier project complied and took all the drugs. He said one significant finding of the project was that there was a complete parasite clearance from the blood streams of patients after 14 days of taking the drug.

Susan G. Komen for the Cure Announces Recipients of 2007 Komen…
Free with registration – PR Newswire – AccessMyLibrary.com – Dec 13, 2007
–>CPYRIGHT 2007 PR Newswire Association LLC University of Southern California Lawrence Berkeley National Laboratory Pioneers Honored for Prevention Studies Widely Adopted Innovations in Biomedical Research DALLAS Dec. Komen for the Cure the global leader in the movement to end breast cancer forever has announced the recipients of the 2007 Komen Brinker Award for Scientific Distinction the organization’s highest award of merit.

EMD Serono Announces Support of The Michael J. Fox Foundation for…
earthtimes.org – Dec 13, 2007
"Additionally while information from other fields must be leveraged in pursuing treatments for PD’s cognitive and psychiatric symptoms simple extrapolation of this knowledge to Parkinson’s is not possible – perhaps due to the pathology of PD and its treatments. "Sherer noted that MJFF and EMD Serono hope through their innovative partnership to encourage Parkinson’s scientists to collaborate with researchers from other areas including psychiatry in order to capitalize on work already done and to obtain different perspectives on cognitive and psychiatric disorders in Parkinson’s disease. The Foundation will accept proposals for clinical research projects or for basic or translational research in relevant preclinical models of PD. Priorities for funding include: — Novel approaches to understanding the pathophysiology of cognitive dysfunction and psychiatric disorders in PD — Development and characterization of pre-clinical models for these symptoms — Examination of the role of cognitive dysfunction and psychiatric disorders in disease onset progression and prognosis — Development or validation of tools to predict or assess early development of cognitive dysfunction and psychiatric disorders in PD — Detailed evaluation of the impact of existing PD treatments on these symptoms — Pre-clinical and clinical testing of available and experimental treatments for cognitive dysfunction and psychiatric disturbances in PD patientsA conference call with MJFF Research Programs staff to further clarify the aims and goals of this initiative will be held Tuesday January 22 at 12 p.